

Catalog # 10-2722 Chymostatin

9076-44-2

[(S)-1-Carboxy-2-phenylethyl]-carbamoyl-a-[2-amidohexahydro-4(S)-pyrimidyl]-(S)-glycyl-[A=Leu, B=Val, C=Ile]-phenylalaninal

Lot # X101433

Chymostatin A R=CH₂CH(CH₃)₂ Chymostatin B R=CH(CH₃)₂ Chymostatin C R=CH(CH₃)CH₂CH₃

A potent, competitive, slow-binding inhibitor of α -, β -, γ -, δ -chymotrypsin, papain and cathepsins B/G (chymotryptase-like serine proteases)¹, K_i =9.36 and 13.1 nM for chymotrypsin and chymase². Cathepsin G K_i =0.15 μ M.³ Consists of a mixture of type A (L-Leu), B (L-Val) and C (L-IIe) forms.¹ Decreases plasma and tissue levels of angiotensin II without lowering mean blood pressure in a hypertensive rat model.⁴ Commonly used in lysis buffers to prevent degradation of proteins. Typical working concentration is 6-60 μ g/ml.

- 1) Umezawa et al. (1970), Chymostatin, a new chymotrypsin inhibitor produced by actinomycetes; J. Antibiot.(Tokyo) **23** 425
- 2) Johnson et al. (1998), Inactivation of chymotrypsin and human skin chymase: kinetics of time-dependent inhibition in the presence of substrate; Biochim.Biophys.Acta **953** 269
- 3) Stein and Strimpler (1987), *Slow-binding of chymotrypsin and cathepsin G by the peptide aldehyde chymostatin*; Biochemistry **26** 2611
- 4) Roszkowska-Chojecka et al. (2015), Effects of chymostatin, a chymase inhibitor, on blood pressure, plasma and tissue angiotensin II, renal haemodynamics and renal excretion in two models of hypertension in the rat; Exp. Physiol. 100 1093

PHYSICAL DATA

Molecular Weight: 605.0 (average) Molecular Formula: $C_{31}H_{41}N_7O_6$ Purity: >96% by TLC

NMR: (Conforms)

Solubility: DMSO (up to 20 mg/ml)
Physical Description: White to Off-white solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.